211 related articles for article (PubMed ID: 31165049)
1. Structural Determinants of the APOBEC3G N-Terminal Domain for HIV-1 RNA Association.
Fukuda H; Li S; Sardo L; Smith JL; Yamashita K; Sarca AD; Shirakawa K; Standley DM; Takaori-Kondo A; Izumi T
Front Cell Infect Microbiol; 2019; 9():129. PubMed ID: 31165049
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for HIV-1 antagonism of host APOBEC3G via Cullin E3 ligase.
Ito F; Alvarez-Cabrera AL; Liu S; Yang H; Shiriaeva A; Zhou ZH; Chen XS
Sci Adv; 2023 Jan; 9(1):eade3168. PubMed ID: 36598981
[TBL] [Abstract][Full Text] [Related]
4. Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface.
Letko M; Booiman T; Kootstra N; Simon V; Ooms M
Cell Rep; 2015 Dec; 13(9):1789-99. PubMed ID: 26628364
[TBL] [Abstract][Full Text] [Related]
5. DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315.
Polevoda B; Joseph R; Friedman AE; Bennett RP; Greiner R; De Zoysa T; Stewart RA; Smith HC
J Biol Chem; 2017 May; 292(21):8642-8656. PubMed ID: 28381554
[TBL] [Abstract][Full Text] [Related]
6. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
7. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.
Ao Z; Yu Z; Wang L; Zheng Y; Yao X
PLoS One; 2008 Apr; 3(4):e1995. PubMed ID: 18414671
[TBL] [Abstract][Full Text] [Related]
8. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
[TBL] [Abstract][Full Text] [Related]
9. Long-term passage of Vif-null HIV-1 in CD4
Miyagi E; Kao S; Fumitaka M; Buckler-White A; Plishka R; Strebel K
Virology; 2017 Apr; 504():1-11. PubMed ID: 28131088
[TBL] [Abstract][Full Text] [Related]
10. Nanoscale Characterization of Interaction of APOBEC3G with RNA.
Pan Y; Sun Z; Maiti A; Kanai T; Matsuo H; Li M; Harris RS; Shlyakhtenko LS; Lyubchenko YL
Biochemistry; 2017 Mar; 56(10):1473-1481. PubMed ID: 28029777
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Escape from Small-Molecule Antagonism of Vif.
Sharkey M; Sharova N; Mohammed I; Huff SE; Kummetha IR; Singh G; Rana TM; Stevenson M
mBio; 2019 Feb; 10(1):. PubMed ID: 30808702
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of APOBEC3G N-domain alone and its complex with DNA.
Xiao X; Li SX; Yang H; Chen XS
Nat Commun; 2016 Aug; 7():12193. PubMed ID: 27480941
[TBL] [Abstract][Full Text] [Related]
13. Translational regulation of APOBEC3G mRNA by Vif requires its 5'UTR and contributes to restoring HIV-1 infectivity.
Guerrero S; Libre C; Batisse J; Mercenne G; Richer D; Laumond G; Decoville T; Moog C; Marquet R; Paillart JC
Sci Rep; 2016 Dec; 6():39507. PubMed ID: 27996044
[TBL] [Abstract][Full Text] [Related]
14. Moloney leukemia virus 10 (MOV10) inhibits the degradation of APOBEC3G through interference with the Vif-mediated ubiquitin-proteasome pathway.
Chen C; Ma X; Hu Q; Li X; Huang F; Zhang J; Pan T; Xia J; Liu C; Zhang H
Retrovirology; 2017 Dec; 14(1):56. PubMed ID: 29258557
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain.
Iwatani Y; Chan DS; Liu L; Yoshii H; Shibata J; Yamamoto N; Levin JG; Gronenborn AM; Sugiura W
Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19539-44. PubMed ID: 19887642
[TBL] [Abstract][Full Text] [Related]
16. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
17. Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA.
Friew YN; Boyko V; Hu WS; Pathak VK
Retrovirology; 2009 Jun; 6():56. PubMed ID: 19497112
[TBL] [Abstract][Full Text] [Related]
18. Structural insights into RNA bridging between HIV-1 Vif and antiviral factor APOBEC3G.
Kouno T; Shibata S; Shigematsu M; Hyun J; Kim TG; Matsuo H; Wolf M
Nat Commun; 2023 Jul; 14(1):4037. PubMed ID: 37419875
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Vif-Mediated Degradation of APOBEC3G through Competitive Binding of Core-Binding Factor Beta.
Miyagi E; Welbourn S; Sukegawa S; Fabryova H; Kao S; Strebel K
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941780
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Vif Gained Breadth in APOBEC3G Specificity after Cross-Species Transmission of Its Precursors.
Chesarino NM; Emerman M
J Virol; 2022 Feb; 96(4):e0207121. PubMed ID: 34908448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
